Study of Investigational Drug in Osteoporosis (MK-0217-908)

Status Completed

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of an investigational drug in postmenopausal women with osteoporosis. The primary hypothesis of this study is that in postmenopausal women with osteoporosis, oral monthly ibandronate, at doses of 100 mg and 150 mg, does not achieve persistence in reduction of bone resorption throughout the monthly dosing interval, as demonstrated by a larger change in the serum carboxyterminal crosslinked telopeptide of Type I collagen (CTX-I) log-transformed fraction from baseline four weeks post dose compared to one week post dose, during the third month of treatment, in the participants taking ibandronate than in the participants taking placebo.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00092053
Study type	Interventional
Source	Organon and Co
Contact
Status	Completed
Phase	Phase 3
Start date	December 2004
Completion date	July 2005

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05902078` - Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis	Phase 4
Completed	`NCT05087030` - Comparative Efficacy and Safety Study of RGB-14-P and Prolia® in Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT01544894` - Clinical Study of Raloxifene and Strontium Ranelate in Postmenopausal Osteoporosis	Phase 4
Completed	`NCT00377819` - Study of Transitioning From Alendronate to Denosumab	Phase 3
Completed	`NCT00381251` - Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.	Phase 1
Completed	`NCT00239629` - Teriparatide and Strontium Ranelate Head-To-Head Comparison Trial	Phase 4
Completed	`NCT04026256` - Bone Modeling Effects of Combined Anabolic/Antiresorptive Administration	Phase 4
Terminated	`NCT00529373` - A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)	Phase 3
Completed	`NCT00092014` - A Study to Evaluate and Compare Alendronate and Risedronate on Bone Mineral Density in Women With Postmenopausal Osteoporosis (MK-0217-211)	Phase 3
Recruiting	`NCT06079476` - A Study of Romosozumab (EVENITY®) in Postmenopausal Women in India With Osteoporosis at a High Risk of Fracture.	Phase 4
Not yet recruiting	`NCT04719650` - Clinical Pharmacokinetics and Pharmacodynamics Study of Different Doses of Zoledronic Acid	Phase 4
Recruiting	`NCT02981732` - CLCF1 Gene Associated With Postmenopausal Osteoporosis of Kidney Yin Deficiency Syndrome	N/A
Completed	`NCT01709110` - VERtebral Fracture Treatment Comparisons in Osteoporotic Women	Phase 4
Completed	`NCT01348243` - Efficacy Of Clodronate 200 Mg/4 Ml I.M. Solution With 1% Lidocaine Every Other Week Vs Clodronate 100 Mg/3,3ml I.M. Solution With 1% Lidocaine Once-Week In A 1-Year Treatment Period Of Women With Postmenopausal Osteoporosis	Phase 3
Completed	`NCT00541658` - A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis	Phase 3
Completed	`NCT00395395` - Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women	Phase 1
Completed	`NCT00247273` - A Study of Monthly Risedronate for Osteoporosis	Phase 3
Active, not recruiting	`NCT03720886` - G56W1 in Women With Postmenopausal Osteoporosis	Phase 1/Phase 2
Completed	`NCT01668589` - Observational Study of Denosumab (Prolia®) in Postmenopausal Women With Osteoporosis	N/A
Completed	`NCT04664959` - A Study to Compare SB16 (Proposed Denosumab Biosimilar) to Prolia® in Postmenopausal Women With Osteoporosis	Phase 3